Filing Details

Accession Number:
0001127602-21-020816
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-29 17:43:16
Reporting Period:
2021-06-28
Accepted Time:
2021-06-29 17:43:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
64803 Cvs Health Corp CVS Retail-Drug Stores And Proprietary Stores (5912) 050494040
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1472795 Alan Lotvin One Cvs Drive
Woonsocket RI 02895
Evp&President-Pharmacyservices No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-28 2,781 $83.67 61,048 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 492 Indirect By Children's Trusts
Common Stock (Restricted) 6,027 Direct
Stock Unit 29,505 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Phantom Stock Credits $1.00 557 557 Direct
Common Stock Stock Option $102.26 2016-04-01 2022-04-01 21,386 21,386 Direct
Common Stock Stock Option $104.82 2017-04-01 2023-04-01 27,395 27,395 Direct
Common Stock Stock Option $78.05 2018-04-03 2024-04-03 32,911 32,911 Direct
Common Stock Stock Option $62.21 2019-04-01 2025-04-01 22,541 22,541 Direct
Common Stock Stock Option $54.19 2020-04-01 2029-04-01 70,702 70,702 Direct
Common Stock Stock Option $58.34 2021-04-01 2030-04-01 140,797 140,797 Direct
Common Stock Stock Option $74.30 2022-04-01 2031-04-01 120,940 120,940 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
557 557 Direct
2022-04-01 21,386 21,386 Direct
2023-04-01 27,395 27,395 Direct
2024-04-03 32,911 32,911 Direct
2025-04-01 22,541 22,541 Direct
2029-04-01 70,702 70,702 Direct
2030-04-01 140,797 140,797 Direct
2031-04-01 120,940 120,940 Direct
Footnotes
  1. All sales were effected pursuant to a Rule 10b5-1 plan.
  2. Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  3. Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  4. Option became exercisable in four equal annual installments, commencing 4/1/2016.
  5. Option became exercisable in four equal annual installments, commencing 4/1/2017.
  6. Option became exercisable in four equal annual installments, commencing 4/3/2018.
  7. Option became exercisable in four equal annual installments, commencing 4/1/2019.
  8. Option became exercisable in four equal annual installments, commencing 4/1/2020.
  9. The number of shares subject to the option were calculated using a 30-day average price.
  10. Option became exercisable in four equal annual installments, commencing 4/1/2021.
  11. Option becomes exercisable in four equal annual installments, commencing 4/1/2022.